The following is a summary of “MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease,” published in the November 2024 issue of Rheumatology by Klein et al.
Researchers conducted a prospective study on the MUC5B rs35705950 promoter variant’s impact on RA-associated interstitial lung disease (RA-ILD) survival.
They studied participants from the Veteran Affairs Rheumatoid Arthritis (VARA) registry with validated ILD diagnoses, followed until death or study end. The MUC5B rs35705950 variant was measured using an Infinium genotyping array, and survival was assessed using Cox regression models, adjusting for confounders.
The results showed that among 263 participants with RA-ILD (mean age 69, 95% male, 73% white, 85% with smoking history), the MUC5B promoter variant was present in 33.5%. Mortality rates were similar between those with (12.2/100PY [95% CI: 9.4, 15.8]) and without (11.1/100PY [95% CI: 9.1, 13.5]) the variant, and MUC5B status was not significantly associated with overall survival (OS) (aHR 0.97 [95% CI: 0.68, 1.37]), survival by ILD pattern, or cause of death (respiratory aHR 0.83 [95% CI: 0.42, 1.66]), non-respiratory (aHR 1.08 [95% CI: 0.72, 1.62]).
They found that the MUC5B promoter variant was linked to RA-ILD risk but not survival. Further studies were needed to identify other prognostic factors for RA-ILD.
Source: academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keae615/7879351
The post Role of the MUC5B Variant in Survival Outcomes for Patients With RA-ILD first appeared on Physician's Weekly.